COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04357106

Acronym

COPLA

Enrollment

Registered

2020-04-22

Start date

2020-04-13

Completion date

2020-08-31

Last updated

2020-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

COVID-19 disease has become a very serious global health problem. Treatments for severe forms are urgently needed to lower mortality. Any procedure that improves these forms should be considered, especially those devoid of serious side effects.There is not enough published information on the use of allogeneic convalescent plasma (ACP) in the treatment of severe forms of COVID-19. The use of ACP can be combined with other treatments and has very few adverse effects. It takes 10-14 days for SARS-CoV2-infected patients to produce virus-neutralizing antibodies: within that time they can develop serious complications and die. Injecting PAC into patients with severe forms of COVID-19 shortens the period of risk while the patient produces the antibodies.

Interventions

BIOLOGICALConvalescent plasma

Convalescent plasma obtained by aphaeresis from recovered patients.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with SARS-CoV2 infection who have had a serious evolution and are in an ICU * With or without ventilatory assistance * Treated or not with hydroxychloroquine 200 mg. every 12 hours * Indistinct sex * Older than 18 years * Signed informed consent

Exclusion criteria

* Patients treated with the following medications: azithromycin, ritonavir / lopinavir, remdesivir, interferons, ruxolinitib, tocilizumab. * Patients with severe kidney failure who require replacement therapy.

Design outcomes

Primary

Measure	Time frame	Description
Lung injury	7 days	PaO2/FiO2 relation
Overall survival	15-30 days	Patients survival after therapy

Secondary

Measure	Time frame	Description
Adverse reactions to plasma	7 days	Determine the incidence of side effects from plasma administration

Countries

Mexico

Contacts

Primary ContactJuan Carlos Olivares-Gazca, MD, MPH

jolivares@hsctmexico.com2222438100

Backup ContactJosé Manuel Priesca-Marin, MD

mpriesca@hsctmexico.com2222438100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026